U.S. Markets closed

Five Companies Hit 52-Week Highs

- By yifan900

According to GuruFocus list of 52-week highs , these Guru stocks have reached their 52-week highs.

Agrium Inc. (AGU) reached the 52-week high of $115.00


Agrium Inc. is a retail supplier of agricultural products and services in North and South America and producer and marketer of agricultural nutrients and industrial products. With more than 1,400 retail centers, Canada-based Agrium is the largest agricultural retailer in the U.S., selling fertilizers, crop chemicals and seed directly to farm customers. The company's wholesale business produces and markets the three main crop nutrients -- nitrogen, potash, and phosphate -- with natural resources located mainly in Canada and the U.S. The bulk of Agrium's sales are generated in the U.S., Canada, and Australia.

The price of Agrium Inc. shares has reached $115.00, which is -1.5% off the 52-week high of $113.25. Agrium Inc. has a market cap of $15.84 billion; its shares were traded around $115.00 with a P/E ratio of 39.72 and P/S ratio of 1.09. The trailing 12-month dividend yield of Agrium Inc. stocks is 3.04%. The forward dividend yield of Agrium Inc. stocks is 3.04%. Agrium Inc. had an annual average earnings growth of 16.10% over the past 10 years.

Agrium Inc. announced recently its 2017 third quarter results, with a net loss from continuing operations of $69 million (52 cents diluted loss per share) compared to a net loss from continuing operations of $38 million (28 cents diluted loss per share) in the third quarter of 2016. The third quarter results were driven by lower overall sales volumes and higher cost of product sold related to several scheduled maintenance turnarounds and higher share-based payments due to a year-to-date total shareholder return of 10% at Sept. 30.

Exelon Corp. (EXCU) reached the 52-week high of $51.95

Exelon Corp. is one of the largest power retailer engaged in the utilities sector of U.S. The company is involved in power generation and transmission activities. Since acquiring Pepco in 2016, Exelon serves more customers than any other U.S. utility, with 10 million power and gas customers at its six regulated utilities in Illinois, Pennsylvania, Maryland, New Jersey, Delaware and Washington, D.C. Exelon owns 11 nuclear plants and 33 gigawatts of generation capacity throughout North America, producing 20% of U.S. nuclear power and 5% of all U.S. electricity. The company is the largest power retailer in the U.S., serving about 200 terawatt-hours of load.

The price of Exelon Corp. shares has reached $51.95, which is 0.8% off the 52-week high of $52.36. Exelon Corp. has a market cap of $33.16 billion; its shares were traded around $51.95 with a P/E ratio of 16.83 and P/S ratio of 1.07. The trailing 12-month dividend yield of Exelon Corp. stocks is 1.56%. The forward dividend yield of Exelon Corp. stocks is 6.26%.

Exelon Corp. recently reported its financial results for the third quarter 2017. Exelon's GAAP Net Income for the third quarter 2017 increased to 85 cents per share from 53 cents per share in the third quarter of 2016; Adjusted (non-GAAP) Operating Earnings decreased to 85 cents per share in the third quarter of 2017 from 91 cents per share in the third quarter of 2016.

Kite Pharma Inc. (KITE) reached the 52-week high of $179.79

Kite Pharma Inc. is a clinical-stage biopharmaceutical company. It is engaged in the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. Kite Pharma is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products. In partnership with the National Cancer Institute through a cooperative research and development agreement, Kite is advancing a pipeline of proprietary product candidates, both chimeric antigen receptor and T-cell receptor products, targeting a wide range of cancer indications. The company also has a strategic collaboration with Amgen to develop and commercialize next-generation CAR-T therapies.

The price of Kite Pharma Inc. shares has reached $179.79, which is 0.1% off the 52-week high of $179.95. Kite Pharma Inc. has a market cap of $10.31 billion; its shares were traded around $179.79 with and P/S ratio of 292.34.

Kite Pharma Inc. recently reported second quarter 2017 financial results and provided a corporate update for the period ended June 30, 2017. Revenue was $10.1 million for the second quarter of 2017. Research and development expenses were $70.9 million for the second quarter of 2017, including $13.1 million of non-cash stock-based compensation expense. General and administrative expenses were $41.1 million for the second quarter of 2017, including $12.1 million of non-cash stock-based compensation expense. Net loss was $109.8 million, or $1.94 per share, for the second quarter of 2017. Non-GAAP net loss for the second quarter of 2017 was $84.7 million, or $1.50 per share, excluding non-cash stock-based compensation expense of $25.2 million.

Anthem Inc. (ANTX) Reached the 52-Week High of $56.51

Anthem Inc. is a health benefits company offering a network-based managed care plans to the large and small employer, individual, Medicaid and Medicare markets. Its business segments are Commercial and Specialty Business, Government Business and Other. With over 40 million medical members, Anthem is one of the largest managed-care organizations in the U.S. The firm provides health insurance services to its members through a plethora of products that encompass every major insurance market -- individual, group and government-sponsored. The firm operates under the highly recognizable Blue Cross/Blue Shield brand in 14 states and has a large nationwide operation.

The price of Anthem Inc. shares has reached $56.51, which is -4.4% off the 52-week high of $54.01. Anthem Inc. has a market cap of $51.83 billion; its shares were traded around $56.51 with a P/E ratio of 16.18 and P/S ratio of 0.69. The trailing 12-month dividend yield of Anthem Inc. stocks is 4.63%. The forward dividend yield of Anthem Inc. stocks is 4.50%. Anthem Inc. had an annual average earnings growth of 9.60% over the past 10 years. GuruFocus rated Anthem Inc. the business predictability rank of 4.5-star .

Anthem Inc. recently reported fourth quarter and full year 2017 financial results. Operating revenues grew 5.8% year-over-year to $89.1 billion. Medical enrollment increased by 325 thousand members in 2017 to 40.2 million members. Fourth quarter net income was $4.67 per share, including net positive adjustment items of $3.38 per share of which $4.21 relates to a one-time, non-cash deferred tax benefit from tax reform. Adjusted net income was $1.29 per share. Full year net income was $14.35 per share, including net positive adjustment items of $2.31 per share. Adjusted net income was $12.04 per share. Operating cash flows grew by 28.0% year-over-year t.o $4.2 billion in 2017.

Bioverativ Inc. (BIVV) Reached the 52-Week High of $103.50

Bioverativ Inc. is a global biotechnology company which focuses on the discovery, research, development and commercialization of innovative therapies for the treatment of hemophilia and other blood disorders. Bioverativ is a biotech focused on rare blood disorders and has two marketed hemophilia products: Eloctate (hemophilia A) and Alprolix (hemophilia B). Bioverativ spun off from Biogen in February 2017. Bioverativ's partner Swedish Orphan Biovitrum holds rights to these therapies and pipeline hemophilia therapies in many markets outside the U.S. Bioverativ is building a pipeline in rare blood-related disorders, such as TNT009 (part of the True North acquisition) in cold agglutinin disease and other hematology-focused drug candidates. Sanofi's pending acquisition of Bioverativ was announced in January 2018.

The price of Bioverativ Inc. shares has reached $103.50, which is 0.8% off the 52-week high of $104.30. Bioverativ Inc. has a market cap of $11.2 billion; its shares were traded around $103.50 with a P/E ratio of 22.04 and P/S ratio of 10.24.

Bioverativ Inc. recently reported financial results for the third quarter of 2017. Key financial results included:

  • Third quarter 2017 revenues of $291.6 million, up 27.2% year-over-year.
  • Third quarter 2017 GAAP net income down 15.7% year-over-year; Non-GAAP net income up 32.8% year-over-year.
  • Third quarter 2017 GAAP earnings per share of 63 cents, down 16.0% year-over-year; Non-GAAP earnings per share of 80 cents, up 31.1% year-over-year.
  • Cash flows from operations of $377.6 million for the nine months ended Sept. 30, 2017.



Note: I do not own these stocks.

This article first appeared on GuruFocus.